ABI 1179
Alternative Names: ABI-1179Latest Information Update: 05 Mar 2025
At a glance
- Originator Gilead Sciences
- Developer Assembly Biosciences
- Class Antivirals; Small molecules
- Mechanism of Action DNA helicase-primase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Herpes simplex virus infections
Most Recent Events
- 20 Feb 2025 Safety and pharmacokinetics data from a phase Ia/Ib trial in Herpes simplex virus infections released by Assembly Biosciences
- 19 Dec 2024 Phase-I clinical trials in Herpes simplex virus infections in New Zealand (PO) prior to December 2024 (NCT06698575)
- 11 Nov 2024 Assembly Biosciences plans a phase I trial for Herpes simplex virus infection in New Zealand (PO) (NCT06698575)